Complementing cell lines
Patent 6492169 Issued on December 10, 2002. Estimated Expiration Date: 
November 15, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
November 15, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod for the production of non-group C adenoviral vectors Packaging systems for human recombinant adenovirus to be used in gene therapy Packaging systems for human recombinant adenovirus to be used in gene therapy Packaging systems for human recombinant adenovirus to be used in gene therapy Patent #: 6306652 InventorsApplicationNo. 713678 filed on 11/15/2000US Classes:435/325, ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide435/235.1, VIRUS OR BACTERIOPHAGE, EXCEPT FOR VIRAL VECTOR OR BACTERIOPHAGE VECTOR; COMPOSITION THEREOF; PREPARATION OR PURIFICATION THEREOF; PRODUCTION OF VIRAL SUBUNITS; MEDIA FOR PROPAGATING435/455Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within an animal cellExaminersPrimary: Housel, James C.Assistant: Foley, Shawn P. Attorney, Agent or FirmInternational ClassesC12N 005/02C12N 007/00 C12N 015/63 AbstractA packaging cell line capable of complemention recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably human embryonic kidney cells and primary human amniocytes) which are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins.Other References
Field of SearchANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORERecombinant DNA technique included in method of making a protein or polypeptide VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.) Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within an animal cell VIRUS OR BACTERIOPHAGE, EXCEPT FOR VIRAL VECTOR OR BACTERIOPHAGE VECTOR; COMPOSITION THEREOF; PREPARATION OR PURIFICATION THEREOF; PRODUCTION OF VIRAL SUBUNITS; MEDIA FOR PROPAGATING DNA or RNA fragments or modified forms thereof (e.g., genes, etc.) |
| ||||||||||||||
